Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (1) · (multiple, generic dominant) (1) · Coreg, Coreg CR (1)

Analgesic (2) · Opioid (2) · Prodrug (1) · with alpha-1 antagonism)]] (1) · [[:Category:Antihypertensives|Antihypertensive]] (1) · [[:Category:Beta blockers|Beta blocker (non-selective (1) · [[:Category:Heart failure medicines|Heart failure medicine]] (1)

Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · '"`UNIQ--vote-00000015-QINU`"' CYP2D6 metabolism produces stereoselective clearance; CYP2D6 poor metabolizers have higher plasma exposure and may need lower doses'"`UNIQ--ref-00000016-QINU`"'. (1)

None (1) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' (1)

None (1) · Adult: 15–60 mg every 4 hours as needed. (1) · Heart failure: 3.125 mg PO BID, doubling every 2 weeks as tolerated to target 25 mg BID (50 mg BID if >85 kg). Hypertension: 6.25 mg PO BID, titrate to 25 mg BID (1)

None (1) · IR tablets 3.125, 6.25, 12.5, 25 mg; Coreg CR capsules 10, 20, 40, 80 mg (once-daily) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (1) · 360 mg/day (1) · 50 mg BID in heart failure (or once-daily equivalent CR); 25 mg BID in hypertension (1)

None (1) · Oral (1) · PO (only formulation marketed in the US). (1)

None (1) · 30–60 min (PO) (1) · Antihypertensive effect within 1 week; heart-failure mortality benefit accrues over months of titration (1)

None (1) · 4–6 hours (1) · ~12 hours (IR); 24 hours (CR) (1)

None (1) · 2.5–3 hours (1) · 7-10 hours'"`UNIQ--ref-0000001B-QINU`"' (1)

None (1) · ~25-35% (extensive first-pass), increased by food which slows absorption and reduces orthostatic risk'"`UNIQ--ref-0000001C-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited human data; β-blocker class effects include fetal growth restriction and neonatal bradycardia/hypoglycemia.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (1)